NovaBay Pharmaceuticals, Inc.
NBYNovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Drugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Experimental: CD07223 1.5 % Topical Gel BID
Impetigo
NVC-422
Impetigo
Auriclosene Solution 0.3%
Bacterial Conjunctivitis
NVC-422 Solution, 0.3%
Adenoviral Conjunctivitis
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Asymptomatic Bacteriuria
NVC-422, 0.2%
Urinary Catheter Blockage and Encrustation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Experimental: CD07223 1.5 % Topical Gel BID | Phase 3 | Impetigo | - | - |
NVC-422 | Phase 2 | Impetigo | - | - |
Auriclosene Solution 0.3% | Phase 2 | Bacterial Conjunctivitis | - | - |
NVC-422 Solution, 0.3% | Phase 2 | Adenoviral Conjunctivitis | - | - |
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate | Phase 2 | Asymptomatic Bacteriuria | - | - |
NVC-422, 0.2% | Phase 2 | Urinary Catheter Blockage and Encrustation | - | - |
Impetigo
2 drugs in this indication
Adenoviral Conjunctivitis
1 drug in this indication
Asymptomatic Bacteriuria
1 drug in this indication
Bacterial Conjunctivitis
1 drug in this indication
Urinary Catheter Blockage and Encrustation
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)